Management of Elevated RBC Count, Eosinophilia, and Basophilia

Initial Diagnostic Workup

A comprehensive history focusing on travel history, new medications, recurrent infections, and family history of autoimmune disease or eosinophilia is recommended by the National Comprehensive Cancer Network, as part of the initial diagnostic workup for patients with elevated RBC count, eosinophilia, and basophilia 1, 2
Physical examination with particular attention to skin evaluation, liver and spleen size, and signs of immunodeficiency is necessary for patients with elevated RBC count, eosinophilia, and basophilia 1
Laboratory testing should include serum tryptase and vitamin B12 levels, which are elevated in myeloproliferative variants of hypereosinophilia, according to the National Comprehensive Cancer Network 1, 2
Serology testing for parasitic infections, especially Strongyloides, is recommended by the National Comprehensive Cancer Network and Clinical Infectious Diseases 2, 3
Quantitative serum immunoglobulin levels, including IgE, should be measured in patients with elevated RBC count, eosinophilia, and basophilia, as recommended by the National Comprehensive Cancer Network 1, 4

Bone marrow aspirate and biopsy with immunohistochemistry for CD117, CD25, and tryptase are necessary for the diagnosis of myeloproliferative disorders, according to the National Comprehensive Cancer Network 1
Cytogenetic analysis with a minimum of 15 metaphases is recommended by Leukemia for the diagnosis of myeloproliferative disorders 5
Fluorescence in situ hybridization (FISH) and/or RT-PCR to detect tyrosine kinase fusion gene rearrangements, particularly PDGFRA, PDGFRB, FGFR1, and PCM1-JAK2, are recommended by the National Comprehensive Cancer Network 1, 2, 6

Myeloid/lymphoid neoplasms with eosinophilia and TK fusion genes should be considered in the differential diagnosis of patients with elevated RBC count, eosinophilia, and basophilia, according to the National Comprehensive Cancer Network 1, 2
Chronic myeloid leukemia (CML) is a potential differential diagnosis for patients with elevated RBC count, eosinophilia, and basophilia, as recommended by Leukemia 5
Parasitic infections, especially helminth infections, should be considered in the differential diagnosis of patients with elevated RBC count, eosinophilia, and basophilia, according to the National Comprehensive Cancer Network and Clinical Infectious Diseases 2, 3, 4
Eosinophilic granulomatosis with polyangiitis (EGPA) is a potential differential diagnosis for patients with elevated RBC count, eosinophilia, and basophilia, as recommended by Nature Reviews Rheumatology 7, 8

If myeloproliferative disorder is confirmed, referral to hematology for specialized management is recommended by the National Comprehensive Cancer Network 1, 6
For myeloid/lymphoid neoplasms with specific genetic abnormalities, targeted therapies such as tyrosine kinase inhibitors may be effective, according to the National Comprehensive Cancer Network 1
If secondary (reactive) eosinophilia is identified, treatment of the underlying cause is necessary, as recommended by the National Comprehensive Cancer Network and Praxis Medical Insights 2, 4

Regular complete blood counts to assess response to treatment are recommended by Praxis Medical Insights 4, 6
Periodic assessment of organ function to detect early signs of end-organ damage is necessary for patients with elevated RBC count, eosinophilia, and basophilia, according to Praxis Medical Insights 6
For patients with myeloid neoplasms, molecular monitoring for minimal residual disease is recommended by Praxis Medical Insights 6

Overlooking potential organ damage in patients with persistent eosinophilia is a common pitfall, according to Praxis Medical Insights 6
Not testing for specific genetic abnormalities that may predict response to targeted therapies is a potential pitfall, as recommended by the National Comprehensive Cancer Network and Praxis Medical Insights 1, 6
Failing to evaluate for parasitic infections, especially in patients with travel history, is a common pitfall, according to the National Comprehensive Cancer Network and Clinical Infectious Diseases 2, 3